Pramodini Medicare IPO

About Pramodini Medicare IPO

The Pramodini Medicare IPO opens on TBA and closes on TBA. The allotment of shares will take place on TBA. The credit of shares to the demat account will take place on TBA. The initiation of refunds will take place on TBA. The listing of shares will take place on TBA.

The offer consists of both a fresh issue and an offer for sale component. The fresh issue will include 53,50,800 shares aggregating up to ₹[TBA] crores. The offer for sale portion includes 5,00,400 shares of ₹10 aggregating up to ₹[TBA] crores. The total number of shares and aggregate amount are yet to be finalised.

Pramodini Medicare IPO’s price band is set at TBA to TBA per share. The lot size for an application is TBA. The minimum amount of investment required by a retail investor is ₹TBA (TBA shares) (based on upper price). The minimum lot size investment for HNI is TBA.

Pramodini Medicare is a diagnostic service provider in India. They provide a range of technology-enabled diagnostic services such as radiology, clinical laboratory and nuclear medicine service to public hospitals, private hospitals, certain PSU (Public Sector Undertaking) of Government of India and medical colleges across tier I, tier II and tier III cities throughout India.

Objectives of Pramodini Medicare IPO

• Funding of capital expenditure for purchase of medical equipment towards existing and proposed diagnostic centres.
  
• General corporate purposes and unidentified inorganic acquisition.
  

Industry Outlook

India is experiencing rapid healthcare expansion driven by government schemes like Ayushman Bharat, growing middle-class demand, and medical tourism. Affordable healthcare provision and rising digital health adoption strengthen its global position.

Technological adoption is transforming healthcare delivery, with telemedicine, AI-driven diagnostics, and robotic surgery reshaping efficiency and patient outcomes. Sustainability initiatives, regulatory frameworks, and a shift toward value-based care highlight future opportunities. Companies focusing on digital health, personalized medicine, and innovation in medical devices and biopharmaceuticals are expected to capture significant growth, making healthcare one of the most resilient and transformative global industries.

About Pramodini Medicare

Pramodini Medicare is a diagnostic service provider in India. They provide a range of technology-enabled diagnostic services such as radiology, clinical laboratory and nuclear medicine service to public hospitals, private hospitals, certain PSU (Public Sector Undertaking) of Government of India and medical colleges across tier I, tier II and tier III cities throughout India. Their diagnostic services include a comprehensive range of offerings:

(i) “Radiology” which covers Magnetic Resonance Imaging (MRI), Computed Tomography (CT scan), X- ray, Ultrasound with colour doppler, Mammography, Dexa Scan and Intervention Radiology.
(ii) “Clinical Laboratory” which includes Haematology, Micro-Biology, Immunology, Pathology & Biochemistry.
(iii) “Nuclear Medicine” which includes PET-CT (Positron Emission Tomography-Computed Tomography), SPECT (Single Photon Emission Computed Tomography) and nuclear therapy.

They also provide teleradiology services through their registered office situated at Vijayawada which functions on a 24×7 basis throughout the year. They provide healthcare services for core testing, patients diagnosis, disease prevention and monitoring of various health conditions. Their services include both routine and specialized tests, which are used for prediction, early detection, diagnostic screening, confirmation and/or monitoring of diseases.

Strengths of Pramodini Medicare

• Establishing a strategic presence across various states of India.
• Strengthening their network with diversified models.
• Technical capability with robust IT infrastructure.
• Dedicated management team with significant industry experience.
• Track record of revenue and financial performance.

Risks of Pramodini Medicare

• A significant portion of their revenue from operations is derived from MOUs with government authorities under Public Private Partnership (PPP) arrangements.
• Concentrated emphasis on radiology services also exposes them to substantial risks that could adversely impact their operations, financial performance, and long-term growth prospects.
• They derive a substantial portion of their revenue from the state of Andhra Pradesh.
• They are majorly dependent on certain key customers cum patients for a substantial portion of their revenues.
• They derive a significant portion of their revenue from government authorities (B2G).

Source: www.nseindia.com and www.bseindia.com

Notes: (1) The figures for Pramodini Medicare are based on Restated Consolidated Financial Statements for the period ended on December 31, 2025 and for the year ended March 31, 2025.

(2) P/E Ratio has been computed based on their respective closing market price on April 22, 2026, as divided by the Basic EPS as on March 31, 2025.

(3) Restated Profit for the year attributable to equity shareholders divided by Net Worth of Pramodini Medicare.

(4) Net asset value per equity share is calculated as net worth as of the end of relevant year divided by the weighted average number of equities shares outstanding at the end of the year.

(5) Price Earning (P/E) Ratio in relation to the Offer Price of [-] per share.

(6) The Price Band determined by Pramodini Medicare and the Promoter Selling Shareholders in consultation with the Book Running Lead Manager is justified by Pramodini Medicare in consultation with the Book Running Lead Manager based on the above parameters.

(7) The peer group companies are not exactly comparable in all aspects of business and services that Pramodini Medicare provides.

Anchor Investor Bidding Date: TBA

Registrar: Purva Sharegistry (India) Private Limited
Book Running Lead Manager: Smart Horizon Capital Advisors Private Limited

Pramodini Medicare Business Model

The company earns its revenue as a diagnostic service provider through four key models namely 1. Public Private Partnership (with government hospitals and government teaching hospitals) 2. Private Private Partnership (with private sector hospitals) 3. Strategic Partnership with PSUs (Public Sector Undertakings) Government of India and 4. Private Centres (standalone centre).

Pramodini Medicare Growth Trajectory

Pramodini Medicare’s Total Income for FY25 was ₹38.546 crores, whereas in FY24 and FY23 it was ₹35.794 crores and ₹30.959 crores, respectively.

The Profit After Tax for FY25 was ₹11.545 crores, whereas in FY24 and FY23 it was ₹7.617 crores and ₹5.875 crores, respectively.

Their EBITDA for FY25 was ₹20.966 crores, whereas in FY24 and FY23 it was ₹15.535 crores and ₹14.672 crores, respectively.

Pramodini Medicare Market Position

As of December 31, 2025, Pramodini Medicare is operating through 15 diagnostic centres. These centres are located in 6 states in India: Uttar Pradesh, Andhra Pradesh, Karnataka, West Bengal, Haryana/NCR Delhi, and Kerala (operation yet to commence). The services offered at each location vary based on the scope agreed under the respective MOUs. They have a presence across 13 cities in India. They also have a processing unit cum laboratory in Vijayawada.

As of 31 March 2025, the company’s Total Income, Profit After Tax, and EBITDA were ₹38.546 crores, ₹11.545 crores, and ₹20.966 crores, respectively.

How to apply for Pramodini Medicare IPO?

• Step 1: Log in to your Kotak Neo Demat account to access IPO investments. Next, select the current IPO section.
• Step 2: Specify IPO details. Enter the number of lots and the price you wish to apply for.
• Step 3: Enter UPI ID. After entering your UPI ID, click submit. This will place your bid with the exchange.
• Step 4: Mandate Notification. Your UPI app will receive a mandate notification to block funds.
• Step 5: Approve Request. Your funds will be blocked once you approve the mandate request on your UPI.